Drug facts

Does compounded semaglutide work?

Quick answer

Semaglutide does: in STEP 1, 2.4 mg a week lowered body weight by 14.9% over 68 weeks, against 2.4% on placebo. No trial has tested a compounded preparation, and semaglutide has a problem of its own on top of that — FDA has warned that some compounders used salt forms of semaglutide, which are different active ingredients from the one in the approved drugs.

What semaglutide does1

STEP 1 results at week 68
STEP 1, 68 weeksSemaglutide 2.4 mgPlacebo
Mean weight change−14.9%−2.4%
Lost 5% or more86.4%31.5%
Lost 10% or more69.1%12.0%
Lost 15% or more50.5%4.9%

That was 1,961 adults without diabetes, double-blind, two-thirds of them on semaglutide and all with a lifestyle program. The thresholds show the spread behind the average: half the semaglutide group lost 15% or more, and half did not. The full summary is on STEP 1, and the head-to-head trials against tirzepatide are on semaglutide against tirzepatide.

On the label — Wegovy / Ozempic

Every figure above was produced with the approved product, at a known dose, under trial supervision.

In a compounded vial

No trial has tested a compounded semaglutide preparation, and FDA says unapproved versions “do not undergo FDA’s review for safety, effectiveness and quality before they are marketed.”

Which semaglutide is in the vial4

With tirzepatide the open question is dose and quality. With semaglutide there is an earlier one: whether the vial contains the same active ingredient at all. FDA, in its own words:

The agency is aware that some semaglutide products sold by compounders may be the salt forms. These salt forms, including semaglutide sodium and semaglutide acetate, are different active ingredients than are used in the approved drugs. The agency does not have information on whether these salts have the same chemical and pharmacologic properties as the active ingredient in the approved drug, and we are not aware of any lawful basis for their use in compounding.

That is the one case on this page where “the molecule is the molecule” may not hold, and the evidence above may not describe what you are injecting. It is a question for the pharmacy, and a fair one to ask before a first order: what exactly is the active ingredient, and where does it come from? What else may be in a compounded vial is on what compounded semaglutide is.

Why it can seem not to work3

Some people lose little on semaglutide itself: in STEP 1, about one in seven of those weighed at week 68 had not lost 5%, and the weight curve flattened after week 60 — both are on not losing weight on semaglutide. The reasons below are timing, and the ones a compounded vial adds.

It is still early. Wegovy’s table calls weeks 1 to 4 the “Starting Dosage” and weeks 5 to 16 the “Dosage Escalation”; maintenance begins at week 17. In STEP 1 nobody started at 2.4 mg — the dose was climbed to. The dosage chart shows where you are on the ladder, and how long semaglutide takes to work covers what the trials saw in those weeks.

The dose is not the dose you think. This is the failure FDA has written about most specifically for semaglutide:4

FDA received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors associated with compounded injectable semaglutide products. These dosing errors resulted from patients measuring and self-administering incorrect doses of the drug, and in some cases, health care professionals miscalculating doses of the drug.

A compounded vial’s concentration is set by the pharmacy, so the same milligram dose is a different mark on the syringe from vial to vial. If you have changed seller or vial, check the arithmetic before the next dose.

The vial is past its use. FDA says a vial holding several doses should be discarded 28 days after first use, and not used at all if it arrived warm — both covered in how long compounded semaglutide lasts.

What happens when it stops2

STEP 4 measured it by taking the drug away. 803 adults who had reached 2.4 mg and lost an average of 10.6% over a 20-week run-in were randomized to continue or switch to placebo. Over the following 48 weeks, those who continued lost a further 7.9%; those switched to placebo regained 6.9%. A result that fades after a gap in supply or a change of seller may be what stopping does, not the new vial failing. The trial is on STEP 4.

Where to take it

To the prescriber, with the vial’s label: the concentration, the dose you draw, the active ingredient if the pharmacy names it, and how long you have been on it. Whether to stay, step up or stop is a clinical decision. If price is what interrupts treatment, the cheapest semaglutide at every dose is what this site can help with.

Questions

Does compounded semaglutide work?
Semaglutide does: in STEP 1, 2.4 mg a week lowered weight by 14.9% over 68 weeks against 2.4% on placebo. No trial has tested a compounded preparation, and FDA has warned that some compounders used salt forms of semaglutide, which are different active ingredients from the approved drug's.
Is compounded semaglutide as effective as Wegovy?
Nobody has measured it. Every efficacy figure for semaglutide was produced with the approved product, and FDA does not review compounded versions for effectiveness before they are marketed.
Why is compounded semaglutide not working for me?
The common reasons are that you are still on the early escalation doses, that the dose is being mismeasured because compounded vials differ in concentration, or that the vial is past 28 days from first use or was exposed to heat. A prescriber can work out which.
What is semaglutide sodium, and is it the same?
It is a salt form of semaglutide. FDA says salt forms, including semaglutide sodium and semaglutide acetate, are different active ingredients from the one in the approved drugs, that it does not know whether they have the same properties, and that it is not aware of any lawful basis for compounding with them.
What happens if you stop compounded semaglutide?
In STEP 4, adults who stopped the approved product after reaching 2.4 mg regained 6.9% of their weight over the next 48 weeks, while those who continued lost a further 7.9%.

Sources

  1. STEP 1, New England Journal of Medicine 2021 (PMID 33567185), as summarized on our research page
  2. STEP 4, JAMA 2021 (PMID 33755728), as summarized on our research page
  3. FDA prescribing information for WEGOVY (semaglutide), section 2.2, revision 6/2026 DailyMed
  4. FDA, 'FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss', content current as of 09/01/2026 FDA